| Ytd | 27.30% | |
| 1y | 102.30% |
| Open | 14.55 | Prev Close | 14.59 | Low | 14.54 | High | 15.20 | Mkt Cap | 1.95B |
| Vol | 3.23M | Avg Vol | 2.57M | EPS | -0.77 | P/E | N/A | Forward P/E | 41.06 |
| Beta | 1.81 | Short Ratio | 6.00 | Inst. Own | 108.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-28 | 50-d Avg | 10.16 | 200-d Avg | 10.21 | 1yr Est | 15.06 |
NEO News
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Carolyn Starrett to its
In addition, NeoGenomics granted the initial purchasers of the notes an option to purchase, for sett
solutions that enable precision medicine, announced today that it has commenced a private offering o
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable prec
Benchmark analyst Bruce Jackson upgrades NeoGenomics (NASDAQ:NEO) from Hold to Buy and announces
TD Cowen analyst Dan Brennan maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price t
Leerink Partners analyst Puneet Souda upgrades NeoGenomics (NASDAQ:NEO) from Market Perform to Ou
NeoGenomics (NASDAQ:NEO) raises FY2026 sales outlook from $793.000 million-$801.000 million to $797.
NeoGenomics (NASDAQ:NEO) reported quarterly earnings of $0.01 per share which met the analyst consen
Through this integration, physicians can order NeoGenomics' comprehensive suite of tests, spanni
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable prec
Piper Sandler analyst David Westenberg maintains NeoGenomics (NASDAQ:NEO) with a Overweight and r
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable prec
Data include findings generated using the RaDaR 1.0 assay to assess molecular residual disease and r
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable prec
Additional presentations to focus on liquid biopsy– MRD based detection and genomic profiling across
NeoGenomics (NASDAQ:NEO) reported quarterly earnings of $0.03 per share which beat the analyst conse
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable prec
Adhishthana.com analysis shows NeoGenomics has chosen the blue pill, consolidation likely to last un
TD Cowen analyst Dan Brennan maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price t
Companies Reporting Before The Bell • EHang Holdings (NASDAQ:EH) is expected to report quarterly lo
Shares of International Flavors & Fragrances Inc. (NYSE: IFF) fell during Wednesday’s session a